פיתוח פרה-קליני: סקירה כללית

Preclinical development consists of four main phases. First, safety pharmacology tests ensure the drug produces no acute harmful effects like bronchoconstriction or cardiac dysrhythmias. Second, preliminary toxicological testing determines the maximum non-toxic dose and examines genetic, reproductive, and carcinogenic effects. Third, pharmacokinetic and pharmacodynamic testing studies the drug's absorption, metabolism, distribution, and elimination. Fourth, chemical and pharmaceutical development focuses on large-scale synthesis, stability assessment, and formulation development.

Safety pharmacology tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia to ensure drugs produce no acutely harmful effects. Animals are treated with the drug for a specified duration and closely monitored for adverse effects. Post-mortem examinations are conducted to detect any signs of tissue damage, providing comprehensive safety data before human testing.

Preliminary toxicological testing determines a drug's maximum non-toxic dose and examines potential genetic, reproductive, and carcinogenic effects. Animals are treated with the drug and monitored for adverse effects including weight loss and tissue damage. Post-mortem examinations help detect any pathological changes, ensuring comprehensive toxicity assessment before advancing to human clinical trials.

Pharmacokinetic and pharmacodynamic testing studies how a drug's absorption, metabolism, distribution, and elimination occur in laboratory animals. These studies establish the relationship between drug exposure and its therapeutic effects, providing critical data on how the body processes the drug and how it produces its intended action before human testing begins.

Chemical and pharmaceutical development focuses on synthesizing the compound on a large scale while ensuring reproducible purity. The stability of drug molecules is tested under various conditions, and suitable formulations are developed for clinical use. This phase ensures the drug can be manufactured consistently and remains stable before submission to regulatory authorities.

An investigator brochure is a detailed dossier prepared for successful drug candidates along with study protocols for submission to regulatory authorities such as the European Medicines Agency or the US FDA. It compiles all preclinical and safety data gathered during development. Permission from the regulatory authority is required to proceed with human studies, and the authority may refuse or request further work before approval.

Approximately half of the identified drug candidates fail during preclinical development. The remaining candidates that successfully pass safety, toxicity, pharmacokinetic, and pharmaceutical testing phases proceed to preparation of the investigator brochure and regulatory submission. This high failure rate underscores the rigorous nature of preclinical screening before human testing begins.